PatrĂ­cia Silva, PhD,  director of science content—

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

Spyryx Biosciences Raises $18 Million To Develop CF Therapy

Spyryx Biosciences, Inc. has successfully raised $18 million in Series A venture capital financing, which will be used to develop novel therapies to treat respiratory conditions such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The funding was secured through deals with Canaan Partners, Hatteras Venture Partners and…

Good Start Genetics Present Positive Results on IVF Genetic Detection Platform

Molecular genetics information company, Good Start Genetics, Inc. has presented data from research being conducted to improve detection of inherited diseases, including cystic fibrosis (CF). The results of two studies that examined detection rates in patients undergoing in vitro fertilization (IVF) were presented  at the 2015 Annual Clinical and Scientific Meeting…

CFF Calls Attention to National Cystic Fibrosis Awareness Month

Last Friday marked the start of national Cystic Fibrosis Awareness Month, when thousands of volunteers across the country will fundraise and advocate for more research to fight the disease. The month-long initiative will be spearheaded by the Cystic Fibrosis Foundation (CFF), which will organize a series of events nationwide. The…

CFFT Awards Corbus $5 Million to Develop Cystic Fibrosis Drug

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) has granted a $5 million development award to clinical stage drug developer Corbus Pharmaceuticals Holdings to support the development process of its investigational drug Resunab to treat cystic fibrosis (CF). The funding from the CFFT, which is the non-profit drug discovery and development affiliate of…

Novel Antibiotic Formulation For Treating Acinetobacter Infections in CF Receives New Drug Application Approval From FDA

The Medicines Company recently announced in a news release that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for a new injectable formulation of the antibiotic MINOCIN® (minocycline). The news is significant for the cystic fibrosis community, as MINOCIN is…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.